Evaluating tacrolimus pharmacokinetic models in adult renal transplant recipients with different CYP3A5 genotypes.

Can HuWen-Jun YinDai-Yang LiJun-Jie DingLing-Yun ZhouJiang-Lin WangRong-Rong MaKun LiuGe ZhouXiao-Cong Zuo
Published in: European journal of clinical pharmacology (2018)
Based on our results, we recommend using model 3 in CYP3A5 extensive metabolizers in clinical practice. All models had a poor predictive performance in CYP3A5 poor metabolizers, and they should be used with caution in this patient population. However, Bayesian forecasting improved the predictability and reduced differences, and thus the models could be applied in this latter patient population for the design of maintenance dose.